EP PerMed - the European Partnership for Personalised Medicine

𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐢𝐬 𝐧𝐨𝐰 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐄𝐏 𝐏𝐞𝐫𝐌𝐞𝐝 𝐉𝐓𝐂2026 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐃𝐚𝐲! 📆 On 16 December 2025, EP PerMed will organise a call information day. With this JTC2026, EP PerMed will fund research projects in human health on innovative #PersonalisedMedicine strategies for patients with #cardiovascular, #metabolic or #kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects: - Innovative personalised therapeutic approaches; - Monitoring of treatment response in patients in order to tailor treatment pathways; - Early disease risk prediction and prevention of disease worsening or comorbidities. 🔗 Registration: https://lnkd.in/eDBMbmnn

We are honoured and proud to receive the EP PerMed Best Practice recognition for our commitment to advancing personalised medicine in paediatric oncology. This award highlights the power of collaboration, innovation, and dedication to improving care for children. Thank you to EP PerMed - the European Partnership for Personalised Medicine for this meaningful acknowledgment — and to all our partners who make this work possible.

The EP PerMed awards Genomic Medicine Sweden (GMS) the title of Best Practice in #PersonalisedMedicine for their national implementation of whole-genome and -transcriptome sequencing in #ChildhoodCancer (GMS Childhood Cancer). The project is dedicated to ensuring that every child diagnosed with cancer in Sweden has access to the most accurate and personalised diagnostics and treatments available.  The project is funded by The Swedish Childhood Cancer Fund (Barncancerfonden), the Swedish Innovation Agency – Vinnova and the Ministry of Health and Social Affairs of Sweden. Read more about GMS Childhood Cancer here: https://lnkd.in/eEpTmN4J image: © Gullers Grupp / Ylva Tegner

On 28 October 2025, EP PerMed organised an call information day about the Research, Innovation and Technology Call (RITC) 2026. The call - with an available budget of over 14.8 Mio. € (approx.) - will fund innovation projects in human health that focus on multimodal data usage for #PersonalisedMedicine approaches providing more efficient and personalised management of patients with multimorbidity, having at least two chronic diseases that require management. 📺 The recording and the slides of the information day are now available: https://lnkd.in/dzdJqniJ 🔗 More on the RITC2026: https://lnkd.in/d8fiQuVq

We are pleased to introduce our speaker Irene Norstedt, Retired/Active Senior at the European Commission. Irene will give a talk on "European Efforts towards #PersonalisedMedicine over the last Decade" and will also be one of our panel experts in "Session 1 - Celebrating the 10th Anniversary of the Council Conclusions on Personalised Medicine and the 1st Strategic Research and Innovation Agenda (SRIA) on Personalised Medicine" on day 1 of the joint ICPerMed - The International Consortium for Personalised Medicine & EP PerMed conference. The conference will be held in Prague, Czech Republic, on 26-27 November 2025. More on the Conference: https://lnkd.in/e7wNBkR5

EP PerMed organised its first Expert Symposium on #PersonalisedMedicine Implementation on 21 October 2025 in Bilbao (Spain). During this one-day event, high-level experts and invited participants showcased and discussed nine different examples of how European national and regional healthcare systems address the implementation of personalised medicine. They focused on the facilitating factors, as well as the gaps and challenges that can impede its adoption within these systems. The discussions revealed that, while national strategies and EU-level policies play a central role, regions are pivotal in delivering care, testing innovations, and deploying infrastructure. EP PerMed will analyse the symposium’s outcomes to further explore these topics and identify the key factors that can contribute to the integration of personalised medicine into adoption strategies, ensuring scalability, equity and sustainability. It also became evident that combining multilevel governance, coordination among regions and nations, patient partnership, and regulatory coherence would increase the successful implementation of personalised medicine for the benefit of European citizens on an equitable basis. The event was organised by the EP PerMed partners Instituto Aragonés de Ciencias de la Salud (IACS) together with BIOEF and the Health Department of the Basque Regional Government Eusko Jaurlaritza - Gobierno Vasco as hosting institutions.

𝐂𝐚𝐥𝐥 𝐏𝐫𝐞-𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭❗ 𝘌𝘗 𝘗𝘦𝘳𝘔𝘦𝘥 𝘑𝘰𝘪𝘯𝘵 𝘛𝘳𝘢𝘯𝘴𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘊𝘢𝘭𝘭 (𝘑𝘛𝘊) 2026 - #𝘗𝘦𝘳𝘴𝘰𝘯𝘢𝘭𝘪𝘴𝘦𝘥𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 𝘧𝘰𝘳 𝘊𝘈𝘙𝘥𝘪𝘰𝘷𝘢𝘴𝘤𝘶𝘭𝘢𝘳, 𝘔𝘌𝘵𝘢𝘣𝘰𝘭𝘪𝘤, 𝘢𝘯𝘥 𝘬𝘪𝘥𝘕𝘦𝘺 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴 (𝘊𝘈𝘙𝘔𝘌𝘕2026) With this JTC2026, EP PerMed will fund research projects in human health on innovative personalised medicine strategies for patients with #cardiovascular, #metabolic or #kidney diseases. The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 38 Mio. € (approx.). Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects: • Innovative personalised therapeutic approaches; • Monitoring of treatment response in patients in order to tailor treatment pathways; • Early disease risk prediction and prevention of disease worsening or comorbidities. The call will launch on 25 November 2025. 🔗 More information on the JTC2026: https://lnkd.in/eENtrcaG The following countries (27) are participating in the preparation of the call: 𝘈𝘶𝘴𝘵𝘳𝘪𝘢*, Belgium, Czech Republic, Denmark, Estonia, Finland, France, 𝘎𝘦𝘳𝘮𝘢𝘯𝘺*, Greece, Hungary, Iceland, Ireland, Israel, 𝘐𝘵𝘢𝘭𝘺*, 𝘓𝘢𝘵𝘷𝘪𝘢*, Lithuania, Luxembourg, Norway, Poland, 𝘗𝘰𝘳𝘵𝘶𝘨𝘢𝘭*, Romania, Slovak Republic, South Africa, Spain, Sweden, 𝘛𝘩𝘦 𝘕𝘦𝘵𝘩𝘦𝘳𝘭𝘢𝘯𝘥𝘴* and 𝘛𝘶𝘳𝘬𝘪𝘺𝘦*. Five of the participating countries are represented by their specific regions (10): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), 𝘚𝘢𝘹𝘰𝘯𝘺 (𝘎𝘦𝘳𝘮𝘢𝘯𝘺)*, 𝘓𝘰𝘮𝘣𝘢𝘳𝘥𝘺 (𝘐𝘵𝘢𝘭𝘺)*, Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain). *𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘰𝘯 𝘱𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘪𝘰𝘯 𝘪𝘴 𝘴𝘵𝘪𝘭𝘭 𝘱𝘦𝘯𝘥𝘪𝘯𝘨